Archive for January, 2011

Incyte Corporation – Phase 2 study of INCB18424 for the treatment of advanced PV and ET

January 3, 2011 2 comments

Incyte Corporation (Incyte Corporation (NASDAQ: INCY) announced positive long-term clinical results from an ongoing open-label Phase 2 trial for INCB18424, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET). PV and ET, along with myelofibrosis (MF), are blood cancers that belong to a group of diseases known as myeloproliferative neoplasms (MPNs). This trial (Study 18424-256) is an ongoing, multi-center, single-arm, open-label study being conducted in the United States and Italy. An initial 8-week run-in evaluation established 10mg and 25mg twice daily as starting doses for expansion cohorts in PV and ET, respectively.

For ET patients: After a median follow-up of 21 months, 49% of enrolled patients (n=39) normalized platelet counts, and 79% achieved platelet counts < 600×109/L or a ≥ 50% reduction from baseline. Of the 14 patients with extreme thrombocytosis > 1000×109/L at baseline, 13 (93%) experienced > 50% reduction. WBC counts for patients with baseline counts > 10×109/L normalized within the first month and were maintained for a median duration of 14 months. Palpable spleens completely resolved in 3 of 4 patients with baseline splenomegaly; 1 reduced >50% from baseline.

INCB18424 is a JAK1 and JAK2 inhibitor that has shown positive clinical activity in a number of hematology and inflammatory conditions.

Incyte Corporation:

Categories: Research Updates


January 3, 2011 7 comments

Welcome to “Life with Essential Thrombocytosis”.

This blog is meant to share experience, knowlege, news of new researches on blood disorder, meeting new friends who also suffered from this disorder and hopefully to share our concerns and hope for a better future to find a cure for this blood disorder. This site does not provide a professional medical opinion and will not be responsible for any medical attention or decision for treatments. Please seek a professional Medical Doctor or a Medical Specialist to diagnose and treat your case.

Essential thrombocytosis (ET, also known as essential thrombocythemia) is a rare chronic blood disorder characterized by the overproduction of platelets by megakaryocytes in the bone marrow in the absence of an alternative cause. In some cases this disorder may be progressive, and rarely may evolve into acute myeloid leukemia or myelofibrosis. It is one of four myeloproliferative disorders.

The following YouTube video by Professor Ruben Mesa, MD from MayoClinic provides a quick and informative overview of ET.